334 related articles for article (PubMed ID: 29754585)
41. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
Kwong YL; Lopes D; Khong PL
Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
[No Abstract] [Full Text] [Related]
42. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
43. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
[TBL] [Abstract][Full Text] [Related]
44. Cutting-edge cancer drug hobbled by diagnostic test confusion.
Ledford H
Nature; 2018 Apr; 556(7700):161-162. PubMed ID: 29636574
[No Abstract] [Full Text] [Related]
45. PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.
Bates SE
Oncologist; 2019 May; 24(5):571-573. PubMed ID: 31088980
[TBL] [Abstract][Full Text] [Related]
46. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
47. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
48. Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.
Sadaat M; Jang S
J Oncol Pract; 2018 Mar; 14(3):198-199. PubMed ID: 29257718
[No Abstract] [Full Text] [Related]
49. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
51. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
52. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Dilley SE; Smith HJ; Straughn JM
Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
[TBL] [Abstract][Full Text] [Related]
53. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
Nan X; Gold KA; Cohen E
Oncology (Williston Park); 2018 Dec; 32(12):617-9, 625-6. PubMed ID: 30632130
[TBL] [Abstract][Full Text] [Related]
55. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
56. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
57. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
[TBL] [Abstract][Full Text] [Related]
58. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
59. Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.
Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Gelber RD; Goldhirsch A
Ann Oncol; 2019 Apr; 30(4):653-655. PubMed ID: 30698647
[No Abstract] [Full Text] [Related]
60. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
